Atopic dermatitis (AD) disproportionately affects children and adolescents, and its intermittent flares of itchy rash profoundly affect their quality of life. Most pediatric patients use prescribed topical corticosteroids for their symptoms; systemic immunomodulators are reserved for severe refractory cases. Pfizer’s nonsteroidal topical agent Eucrisa and Sanofi/Regeneron’s Dupixent—for which we expect FDA approval for adolescent AD patients in 2019—bring new options to distinct points in the AD treatment algorithm. This claims data analysis assesses how these novel agents have begun to be integrated into patients’ treatment, as well as how they compare with the therapeutic mainstays.
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed pediatric AD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric AD patients?
- How have Dupixent and Eucrisa been integrated into the treatment algorithm for pediatric AD, and what are their sources of business?
- What percentage of pediatric AD patients receive drug therapy within one year of diagnosis, and how quickly do they receive it? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of pediatric AD patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations? What are the product-level compliance and persistency rates among drug-treated pediatric AD patients?
KEY DRUGS COVERED
Dupixent, Eucrisa, Protopic, Elidel, cyclosporine, methotrexate, azathioprine, mycophenolate mofetil, topical corticosteroids
KEY ANALYSIS PROVIDED
Brand/therapy usage across a longitudinal patient sample.
Newly diagnosed patient analysis.
Treatment initiation and progression.
Line of therapy analysis.
Combination therapy analysis.
Source of business for recently treated patients.
Persistency and compliance analysis.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.